Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Studies of von Willebrand Factor (VWF)-platelet interactions in vitro and in vivo
EF 2024-25
Résumé
Blood clotting is a fine balance between preventing bleeding and stopping harmful clots from forming. von Willebrand Factor (VWF) is a blood molecule that plays a key role in this process by helping platelets (small blood cells) stick to sites of blood vessels to form a protective “plug”. However, too much VWF activity can lead to excessive platelet plugs and clots which can contribute to conditions like heart attacks and strokes. Another protein, ADAMTS13, helps regulate VWF by breaking it down into smaller, less sticky fragments. When ADAMTS13 levels are too low, excessive VWF activity can increase clot risk. This study will analyze how VWF behaves in the context of flowing blood, simulating real conditions in blood vessels. We will use a “microfluidic flow assay”, which mimics blood flow, to observe how VWF interacts with platelets. We will compare blood samples from healthy volunteers and patients with heart disease or stroke to see how these blood samples influence VWF-platelet interactions. We will also measure blood molecules involved in inflammation, as certain inflammatory molecules in the blood may worsen VWF’s sticky behaviour. In addition, we will test if adding ADAMTS13 can reduce the number of VWF-platelet strings. This will be studied both in the microfluidic system and in a mouse model of arterial clotting. In the mice, fluorescent imaging will track how clots form in blood vessels and whether ADAMTS13 can help reduce blood clot size. Overall, these findings could lead to new treatments for diseases caused by abnormal blood clots, using ADAMTS13 to restore balance in clotting. This approach might help people at risk of heart attacks, strokes, and other clot-related disorders, making it a promising area of research.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530075
Name
Gyorffy Vanessa J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Studies of von Willebrand Factor (VWF)-platelet interactions in vitro and in vivo
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adamts13; Arterial Thrombosis; Blood Vessels; Cardiovascular Disease; Endothelial Cells; Microfluidic Technology; Mouse Models; Plasma Samples; Platelets; Von Willebrand Factor (Vwf)
Abstract
Blood clotting is a fine balance between preventing bleeding and stopping harmful clots from forming. von Willebrand Factor (VWF) is a blood molecule that plays a key role in this process by helping platelets (small blood cells) stick to sites of blood vessels to form a protective “plug”. However, too much VWF activity can lead to excessive platelet plugs and clots which can contribute to conditions like heart attacks and strokes. Another protein, ADAMTS13, helps regulate VWF by breaking it down into smaller, less sticky fragments. When ADAMTS13 levels are too low, excessive VWF activity can increase clot risk. This study will analyze how VWF behaves in the context of flowing blood, simulating real conditions in blood vessels. We will use a “microfluidic flow assay”, which mimics blood flow, to observe how VWF interacts with platelets. We will compare blood samples from healthy volunteers and patients with heart disease or stroke to see how these blood samples influence VWF-platelet interactions. We will also measure blood molecules involved in inflammation, as certain inflammatory molecules in the blood may worsen VWF’s sticky behaviour. In addition, we will test if adding ADAMTS13 can reduce the number of VWF-platelet strings. This will be studied both in the microfluidic system and in a mouse model of arterial clotting. In the mice, fluorescent imaging will track how clots form in blood vessels and whether ADAMTS13 can help reduce blood clot size. Overall, these findings could lead to new treatments for diseases caused by abnormal blood clots, using ADAMTS13 to restore balance in clotting. This approach might help people at risk of heart attacks, strokes, and other clot-related disorders, making it a promising area of research.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gyorffy, Vanessa J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~